Thank you for joining us in 2022!

Lung Cancer Immunotherapy

November 12, 2022, 4:20 pm -
4:50 pm
Breakthrough treatments for longer life

Session Description

As the most common cancer worldwide, lung cancer impacts approximately 2.1 million people each year. Hope for millions is on the horizon as the lung cancer death rate in the United States has dropped dramatically over the last few years with the introduction of new treatments, including immunotherapy. Immunotherapy for lung cancer, alone or in combination with conventional treatments, can significantly improve outcomes for lung cancer patients. Join medical oncologist Dr. Julie Brahmer, of Johns Hopkins Medicine, to hear about several recently approved immunotherapy options and ask your questions about how immunotherapy is advancing the treatment of lung cancer. We’ll discuss PD-L1 expression, treatment response, length of treatment, clinical trials, and more.


Julie Brahmer, MD

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Julie R. Brahmer, MD, MSc, is the Director of the Thoracic Oncology Program, Professor of Oncology, and Marilyn Meyerhoff Professor in Thoracic Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. In addition to serving as Co-Leader of the Cancer Immunology Program, she also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus. She is co-principal investigator of the Johns Hopkins’ National Clinical Trials Network and helps direct all oncology cooperative group activities on the Johns Hopkins campuses. Dr. Brahmer is an international leader in lung cancer clinical trials research with particular expertise in drug development for thoracic malignancies and immunotherapy. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center, College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, she later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer’s research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the Johns Hopkins Kimmel Cancer Center immunotherapy related toxicity management team and co-leads ASCO, NCCN, and SITC toxicity guideline development for these national and international organizations.